Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
53 studies found for:    Open Studies | "hospital of central connecticut"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "hospital of central connecticut"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Cardiovascular Inflammation Reduction Trial
Condition: Cardiovascular Disease
Interventions: Drug: Methotrexate;   Drug: Placebo
2 Recruiting Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Condition: Chronic Lymphocytic Leukemia
Intervention:
3 Recruiting Connect® MM- The Multiple Myeloma Disease Registry
Condition: Multiple Myeloma
Intervention:
4 Recruiting Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
Conditions: Endometrial Clear Cell Adenocarcinoma;   Ovarian Clear Cell Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Dasatinib;   Other: Laboratory Biomarker Analysis
5 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Doxorubicin Hydrochloride;   Drug: Docetaxel;   Drug: Cyclophosphamide;   Biological: Trastuzumab;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
6 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib;   Biological: Rituximab;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
7 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Docetaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
8 Recruiting Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer
Interventions: Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
9 Recruiting Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Conditions: Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Drug: Lenalidomide;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Prednisone;   Other: Laboratory Biomarker Analysis
10 Recruiting Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Conditions: Platinum Sensitive;   BRCA Mutated;   Relapsed Ovarian Cancer;   Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Drug: Olaparib 300mg tablets;   Drug: Placebo to match olaparib 300mg
11 Recruiting Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Conditions: Gestational Trophoblastic Tumor;   Hydatidiform Mole;   Low Risk Metastatic Gestational Trophoblastic Tumor;   Uterine Choriocarcinoma
Interventions: Drug: leucovorin calcium;   Biological: dactinomycin;   Drug: methotrexate;   Procedure: quality-of-life assessment
12 Recruiting Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
Conditions: HER2/Neu Positive;   Male Breast Carcinoma;   Metastatic Malignant Neoplasm to the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Drug: Lapatinib Ditosylate;   Radiation: Whole-Brain Radiotherapy;   Other: Laboratory Biomarker Analysis
13 Recruiting Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
Condition: Cervical Cancer
Interventions: Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
14 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Quality-of-Life Assessment
15 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Sexuality and Reproductive Issues;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: cisplatin;   Drug: paclitaxel;   Drug: carboplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Other: quality-of-life assessment
16 Recruiting Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Drug: daunorubicin hydrochloride;   Other: clinical observation;   Drug: cytarabine;   Drug: decitabine;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
17 Recruiting Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Salivary Gland Squamous Cell Carcinoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Major Salivary Gland Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Tongue Carcinoma;   Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary
Interventions: Drug: Docetaxel;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Fluorouracil;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Cytology Specimen Collection Procedure
18 Recruiting Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer
Conditions: Lymphedema;   Stage IA Cervical Cancer;   Stage IA Endometrial Carcinoma;   Stage IA Vulvar Cancer;   Stage IB Cervical Cancer;   Stage IB Endometrial Carcinoma;   Stage IB Vulvar Cancer;   Stage II Endometrial Carcinoma;   Stage II Vulvar Cancer;   Stage IIA Cervical Cancer;   Stage IIIA Vulvar Cancer;   Stage IIIB Vulvar Cancer;   Stage IIIC Vulvar Cancer;   Stage IVB Vulvar Cancer
Interventions: Procedure: therapeutic lymphadenectomy;   Procedure: therapeutic conventional surgery;   Procedure: therapeutic laparoscopic surgery;   Procedure: study of high risk factors;   Other: questionnaire administration;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
19 Recruiting Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Conditions: Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Pancreatic Intraductal Papillary-Mucinous Neoplasm;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: Gemcitabine Hydrochloride;   Drug: Erlotinib Hydrochloride;   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Capecitabine;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
20 Recruiting Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
Interventions: Drug: Lenalidomide;   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years